4584 Stock Overview
Develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kidswell Bio Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥106.00 |
| 52 Week High | JP¥185.00 |
| 52 Week Low | JP¥88.00 |
| Beta | 0 |
| 1 Month Change | -3.64% |
| 3 Month Change | -2.75% |
| 1 Year Change | -19.70% |
| 3 Year Change | -75.52% |
| 5 Year Change | -89.41% |
| Change since IPO | -69.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4584 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 1.9% | 1.5% | 1.2% |
| 1Y | -19.7% | 17.7% | 8.4% |
Return vs Industry: 4584 underperformed the JP Biotechs industry which returned 15.7% over the past year.
Return vs Market: 4584 underperformed the JP Market which returned 7.4% over the past year.
Price Volatility
| 4584 volatility | |
|---|---|
| 4584 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4584 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4584's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Shinya Kurebayashi | www.kidswellbio.com |
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease.
Kidswell Bio Corporation Fundamentals Summary
| 4584 fundamental statistics | |
|---|---|
| Market cap | JP¥4.31b |
| Earnings (TTM) | -JP¥301.95m |
| Revenue (TTM) | JP¥1.88b |
0.0x
P/S Ratio0.0x
P/E RatioIs 4584 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4584 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.88b |
| Cost of Revenue | JP¥721.70m |
| Gross Profit | JP¥1.16b |
| Other Expenses | JP¥1.46b |
| Earnings | -JP¥301.95m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4584 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 06:51 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kidswell Bio Corporation is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hironoshin Nomura | Mizuho Securities Co., Ltd. |
| Shinya Tsuzuki | Mizuho Securities Co., Ltd. |
| Motoya Kohtani | Nomura Securities Co. Ltd. |